Cypralis appoints a new Chief Scientific Officer
2 March 2016 | By Victoria White
Cypralis, a company focussed on the discovery of novel therapeutics based on modulation of PPIases, has appointed Dr Michael Peel as Chief Scientific Officer...
List view / Grid view
2 March 2016 | By Victoria White
Cypralis, a company focussed on the discovery of novel therapeutics based on modulation of PPIases, has appointed Dr Michael Peel as Chief Scientific Officer...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...